User profiles for "author:Krammer F"
 | Florian KrammerIcahn School of Medicine at Mount Sinai Verified email at mssm.edu Cited by 60819 |
SARS-CoV-2 vaccines in development
F Krammer - Nature, 2020 - nature.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in late
2019 in China and is the causative agent of the coronavirus disease 2019 (COVID-19) …
2019 in China and is the causative agent of the coronavirus disease 2019 (COVID-19) …
The human antibody response to influenza A virus infection and vaccination
F Krammer - Nature Reviews Immunology, 2019 - nature.com
The adaptive immune response to influenza virus infection is multifaceted and complex,
involving antibody and cellular responses at both systemic and mucosal levels. Immune …
involving antibody and cellular responses at both systemic and mucosal levels. Immune …
Advances in the development of influenza virus vaccines
F Krammer, P Palese - Nature reviews Drug discovery, 2015 - nature.com
Influenza virus infections are a major public health concern and cause significant morbidity
and mortality worldwide. Current influenza virus vaccines are an effective countermeasure …
and mortality worldwide. Current influenza virus vaccines are an effective countermeasure …
A serological assay to detect SARS-CoV-2 seroconversion in humans
Here, we describe a serological enzyme-linked immunosorbent assay for the screening and
identification of human SARS-CoV-2 seroconverters. This assay does not require the …
identification of human SARS-CoV-2 seroconverters. This assay does not require the …
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19
INTRODUCTION Clinical outcomes of human severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection range from silent infection to lethal coronavirus …
coronavirus 2 (SARS-CoV-2) infection range from silent infection to lethal coronavirus …
[HTML][HTML] Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals
Understanding adaptive immunity to SARS-CoV-2 is important for vaccine development,
interpreting coronavirus disease 2019 (COVID-19) pathogenesis, and calibration of …
interpreting coronavirus disease 2019 (COVID-19) pathogenesis, and calibration of …
[HTML][HTML] SARS-CoV-2 vaccines: status report
F Amanat, F Krammer - Immunity, 2020 - cell.com
SARS-CoV-2, the causal agent of COVID-19, first emerged in late 2019 in China. It has since
infected more than 870,000 individuals and caused more than 43,000 deaths globally. Here …
infected more than 870,000 individuals and caused more than 43,000 deaths globally. Here …
NAction! How can neuraminidase-based immunity contribute to better influenza virus vaccines?
F Krammer, RAM Fouchier, MC Eichelberger… - MBio, 2018 - journals.asm.org
Neuraminidase is one of the two surface glycoproteins of influenza A and B viruses. It has
enzymatic activity that cleaves terminal sialic acid from glycans, and that activity is essential …
enzymatic activity that cleaves terminal sialic acid from glycans, and that activity is essential …
Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron
Abstract The Omicron (B. 1.1. 529) variant of severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) was initially identified in November 2021 in South Africa and Botswana, as …
2 (SARS-CoV-2) was initially identified in November 2021 in South Africa and Botswana, as …
[HTML][HTML] Immunology of COVID-19: current state of the science
The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has affected millions of people worldwide, igniting …
syndrome coronavirus 2 (SARS-CoV-2) has affected millions of people worldwide, igniting …